For personal use only

RACURA ONCOLOGY

Quarterly Report & 4C

June 2026

For personal use only

ASX Announcement

June 2026 Quarterly Activity Report & Appendix 4C

- **First patient treated with RC220 in the Phase 1 HARNESS-1 trial for patients with EGFR-mutated non-small cell lung cancer**
- **Presented data at the 2026 American Association for Cancer Research Annual Meeting, showing (E,E)-bisantrene's ability to silence c-MYC gene expression**
- **Phase 1 Cardioprotection and Anticancer Synergy (CPACS) trial cleared to escalate to the next designated RC220 dose level of 80mg/m²**
- **Cash balance of $34.3 million at 30 June 2026, provides funding into CY2028**

28 July 2026

Racura Oncology Limited ("Racura" or the "Company") is pleased to release its Q4 FY2026 report for the period ended 30 June 2026, highlighting robust funding capacity and continued execution across its RC220 clinical development strategy. At quarter end, Racura held cash and cash equivalents of $34.3 million, with more than 75% of expenditure in the quarter ($2.45 million) invested in R&D and drug manufacturing activities. This strong cash position is expected to fund all committed activities into CY2028, providing a clear runway to advance key clinical milestones.

Racura delivered significant progress across its clinical and corporate programs during the quarter. In April, Racura presented new preclinical data at the 2026 American Association for Cancer Research (AACR) Annual Meeting on RC220's mechanism of action and its ability to silence expression of the important oncogene c-MYC which is dysregulated in up to 70% of all cancers.

In May a favourable safety review, with no dose-limiting toxicities, enabled the CPACS Phase 1 trial to advance to the next RC220 dose level, further supporting RC220's safety profile and clinical development. In the same month, the Company entered into a no-fee underwriting agreement, ensuring full exercised of the Piggyback Options and contributing to the $18 million raised in the quarter.

In June, Racura attracted a new specialist institutional investor through a small strategic placement of $1 million. Late in the month, the first patient was treated in the Phase 1 HARNESS-1 trial evaluating RC220 in combination with osimertinib for patients with EGFR-mutated non-small cell lung cancer (NSCLC), marking another important clinical milestone.

For personal use only

Management commentary

Chief Executive Officer and Managing Director Dr. Daniel Tillett commented: *"The June quarter was transformational for Racura as we delivered strong clinical progress, strengthened our balance sheet with the support of our shareholders, and advanced the clinical development of RC220 across multiple high-value MYC-focused oncology programs. With $34.3 million in cash, we are funded to support our clinical activities into CY2028 and well placed to execute on our commercial strategy across AML, EGFR-mutated lung cancer and anthracycline cardioprotection. The progress of the CPACS trial to the next dose level, first patient treatment in the HARNESS-1 trial, and new data supporting RC220's MYC-silencing mechanism of action, all strengthen the value of our lead asset RC220. We are excited by the opportunities ahead and remain focused on delivering real value for patients and shareholders."*

Key events of the quarter

- On 22 April 2026, Racura Senior Scientist Dr Sumit Sahni presented new preclinical data at the 2026 American Association for Cancer Research (AACR) Annual Meeting in San Diego. The data showed that (E,E)-bisantrene silences c-MYC gene expression by binding to and stabilising G-quadruplex (G4) DNA structures in the c-MYC promoter region, further clarifying the mechanism of action for Racura's lead asset RC220 and underpinning our current and future clinical development programs.
- On 15 May 2026, Racura announced that its Phase 1 Cardioprotection and Anticancer Synergy (CPACS) trial had been cleared to escalate to the next designated RC220 dose level of 80mg/m². After reviewing safety and pharmacokinetic data from the first patient cohort, the Safety Review Committee identified no dose-limiting toxicities or treatment-related safety concerns, allowing continued dose escalation. The trial is underway in Australia, Hong Kong and South Korea.
- On 28 May 2026, Racura announced a no-fee underwriting agreement with the support of an existing shareholder Dr AJ Robinson for the $1.25 Piggyback Options. Dr Robinson previously supported a private placement of $3.22m in December 2025. The full conversion of the Piggyback Options raised $25.2 million, supporting Racura's clinical programs and balance sheet. We thank Dr Robinson for his generous funding of Racura and our mission.
- On 4 June 2026, Racura announced a small strategic private placement to a specialist institutional investor focused on emerging healthcare companies. The placement comprised 526,315 new shares issued at $1.90 per share, raised $1 million and enabled the institutional investor to establish an initial equity position in Racura.
- On 16 June 2026, Racura announced it had raised a total of $34.3 million since 2025 through fundraising initiatives including Bonus and Piggyback Option conversions, private placements and option underwriting. The funds support Racura's RC220 clinical programs in acute myeloid leukaemia (AML), EGFR-mutated non-small cell lung cancer and anthracycline cardioprotection in solid tumour patients, as well as provide general working capital.

For personal use only

- On 25 June 2026, Racura announced that the first patient had been treated with RC220 in the Phase 1 HARNESS-1 clinical trial evaluating RC220 in combination with osimertinib for patients with EGFR-mutated non-small cell lung cancer (NSCLC). The first patient was treated by Principal Investigator Associate Professor Surein Arulananda and his team at Monash Health in Clayton, Victoria, with no adverse events observed during or after RC220 infusion.

Other news from the quarter

- Dr Feroz Ahmad and Prof Michael Kelso travelled to China to audit Racura's suppliers and visit potential clinical collaborators. The audit formed part of Racura's ongoing quality assurance and oversight activities.
- Dr Suzanne McCusker joined the Company as Corporate Operations Manager, bringing extensive experience in corporate operations, governance and business management. Since joining, she has enhanced the Company's operational effectiveness and organisational planning.

Post quarter news

- On 3 July 2026, Racura announced the Bellberry Human Research Ethics Committee (HREC) had approved the HARNESS-1 lung cancer trial, allowing additional Australian clinical trial sites outside of Victoria to join the study. Following ethics approval, Chris O'Brien Lifehouse and Austin Health progressed to governance and start-up activities, supporting increased patient recruitment and the ongoing evaluation of RC220 in combination with osimertinib for patients with EGFR-mutated non-small cell lung cancer (NSCLC).
- From 15 to 17 July 2026, Dr Rodney Cusack and Dr Feroz Ahmad attended the Thoracic Oncology Group of Australasia (TOGA) Annual Scientific Meeting in Melbourne. The meeting provided an opportunity to engage with leading lung cancer clinicians, researchers and industry representatives and discuss the science behind (E,E)-bisantrene and RC220 in the HARNESS-1 clinical trial, enhancing Racura's engagement with emerging leaders and developments in thoracic oncology.

For personal use only

Summary of cash flow and quarterly activity

As of 30 June 2026, Racura held cash and equivalents of $34.3 million.

Listing rule 4.7C.3

Payments during the quarter to Related Parties amounted to $129k, comprising payments of salaries and superannuation to Executive Directors of $88k and board fees to Non-Executive Directors of $41k.

Shareholders by holding range as of 30 June 2026

During the quarter, Racura increased both its total shareholder count and the number of shareholders holding more than 5,000 shares, reflecting continued growth in its shareholder base.

Holding Ranges	Holders	Total Units	% Issued Capital
Above 0 up to and including 1,000	4,157	1,698,583	0.87%
Above 1,000 up to and including 5,000	2,780	6,912,333	3.53%
Above 5,000 up to and including 10,000	861	6,447,001	3.29%
Above 10,000 up to and including 100,000	1,649	52,701,791	26.88%
Above 100,000	315	128,309,232	65.44%
Total	**9,762**	**196,068,940**	**100%**

For personal use only

Top 20 holders as of 30 June 2026

Racura is pleased to share the current Top 20 shareholders as of 30 June 2026. Shareholders can expect regular updates in future quarterly reports.

Position	Holder	Holding	% IC
1	DR DANIEL TILLETT	20,179,730	10.29%
2	MR PHILLIP RICHARD PERRY	7,421,138	3.79%
3	MR MARK PHILLIP JUAN	6,068,376	3.10%
4	DR BORJE SVEN ANDERSSON	3,750,005	1.91%
5	THE TRUST COMPANY (AUSTRALIA) LIMITED <MOF A/C>	3,420,000	1.74%
6	BNP PARIBAS NOMINEES PTY LTD <IB AU NOMS RETAILCLIENT>	2,346,276	1.20%
7	KUDOSS INVESTMENTS PTY LTD <AITKEN GLOBAL FAMILY A/C>	2,314,450	1.18%
8	MR PHILLIP RICHARD PERRY & MRS TETYANA PERRY <DONESKA SUPER FUND A/C>	2,068,500	1.06%
9	MR SANDOR HELBY	2,043,000	1.04%
10	MR KIMBERLEY ROSS GARTRELL & MRS JENNIFER MARGARET GARTRELL <K&J GARTRELL SUPER FUND A/C>	1,755,000	0.90%
11	MR ANTHONY JAMES ROBINSON <THE PEEKO FAMILY NO 86 A/C>	1,372,544	0.70%
12	MS MARINELLA MESSINA	1,369,954	0.70%
13	MR ALAN GILES SAURAN	1,333,888	0.68%
14	SURPION PTY LTD <M W SUHR & CO A/C>	1,250,000	0.64%
15	MR BRIAN JAMES WALKER	1,175,094	0.60%
16	CITICORP NOMINEES PTY LIMITED	1,174,785	0.60%
17	MR MARK PHILLIP JUAN	1,149,164	0.59%
18	MR BEAU THOMAS ROBINSON <BEAU ROBINSON INVSTMNT A/C>	966,760	0.49%
19	3RD MAN RISK CONSULTING PTY LIMITED	815,000	0.42%
20	MR ROSS EARL HENRY	800,000	0.41%
	Total	62,773,664	32.02%
	Total issued capital	**196,068,940**	**100.00%**

-ENDS-

For personal use only

About Racura Oncology

Racura Oncology (ASX: RAC) is a Phase 3 clinical-stage biopharmaceutical company with a mission to silence cancer.

Racura's lead asset, (E,E)-bisantrene, is a clinically derisked small-molecule anticancer agent that primarily acts by stabilising G4-DNA and RNA structures, driving potent silencing of c-MYC, a key cancer gene dysregulated in up to 70% of all cancers. (E,E)-bisantrene has shown therapeutic activity in cancer patients and has a well-characterised safety profile. Racura's discoveries have supported composition-of-matter IP filings that, if granted, could provide up to 20 years of patent protection for (E,E)-bisantrene.

Racura is advancing RC220, its proprietary formulation of (E,E)-bisantrene, to address significant unmet need across multiple MYC-driven oncology indications. The Company's clinical programs include the Phase 3 EMILI trial in acute myeloid leukaemia, the Phase 1a/b HARNESS trial in combination with osimertinib for EGFR-mutated non-small cell lung cancer, and the Phase 1a/b CPACS trial in combination with doxorubicin, where Racura aims to deliver both anthracycline cardioprotection and enhanced anticancer activity.

Racura has collaborated with Astex, Emory University, Purdue University, MD Anderson, Sheba City of Health, UNC School of Medicine, the University of Wollongong and the University of Newcastle. Racura is actively exploring partnerships, licence agreements and potential commercial merger and acquisition opportunities to accelerate global patient access to RC220. Learn more at www.racuraoncology.com.

For questions about this announcement or previous Racura Oncology announcements, please visit our Interactive Announcements page.

Racura encourages investors to go paperless by registering their email details with the Company's share registry, Automic Registry Services, at www.automicgroup.com.au.

Release authorised by

Daniel Tillett, CEO & MD

info@racuraoncology.com

Media Contact

Cherie Hartley +61 418 737 020

cherie.hartley@irdepartment.com.au

RACURA ONCOLOGY LIMITED (RAC)

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

RACURA ONCOLOGY LIMITED (RAC)

ABN	**Quarter ended ("current quarter")**
61 149 318 749	30 June 2026

Consolidated statement of cash flows		**Current quarter $A'000**	**Year to date (12 months) $A'000**
1.	**Cash flows from operating activities**		
1.1	Receipts from customers	-	-
1.2	Payments for		
	(a) research and development	(2,136)	(7,462)
	(b) product manufacturing and operating costs	(309)	(1,061)
	(c) advertising and marketing	(106)	(492)
	(d) leased assets	-	-
	(e) staff costs	(259)	(1,088)
	(f) administration and corporate costs	(412)	(1,568)
1.3	Dividends received (see note 3)	-	-
1.4	Interest received	174	613
1.5	Interest and other costs of finance paid	-	-
1.6	Income taxes paid	-	-
1.7	Government grants and tax incentives	-	2,780
1.8	Other (provide details if material)	-	31
1.9	**Net cash from / (used in) operating activities**	**(3,048)**	**(8,247)**

2.	**Cash flows from investing activities**		
2.1	Payments to acquire or for:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	(4)	(4)
	(d) investments	-	-

For personal use only

Consolidated statement of cash flows		Current quarter $A'000	Year to date (12 months) $A'000
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	1
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	**Net cash from / (used in) investing activities**	**(4)**	**(3)**

3.	**Cash flows from financing activities**		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	1,637	4,860
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	16,329	24,011
3.4	Transaction costs related to issues of equity securities or convertible debt securities	-	-
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	-	-
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (share buy-back)	-	-
3.10	**Net cash from / (used in) financing activities**	**17,966**	**28,871**

4.	**Net increase / (decrease) in cash and cash equivalents for the period**		
4.1	Cash and cash equivalents at beginning of period	19,376	13,666
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(3,048)	(8,247)

For personal use only

Consolidated statement of cash flows		Current quarter $A'000	Year to date (12 months) $A'000
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(4)	(3)
4.4	Net cash from / (used in) financing activities (item 3.10 above)	17,966	28,871
4.5	Effect of movement in exchange rates on cash held	-	3
4.6	**Cash and cash equivalents at end of period**	**34,290**	**34,290**

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter $A'000	Previous quarter $A'000
5.1	Bank balances	3,290	1,876
5.2	Call deposits	31,000	17,500
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	**Cash and cash equivalents at end of quarter (should equal item 4.6 above)**	**34,290**	**19,376**

6.	Payments to related parties of the entity and their associates	Current quarter $A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	129
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-

Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.

Payment to related parties as disclosed in item 6.1 as follows:

- $40,572 payments for non-executive director fees for the period;
- $88,036 payments to executive directors for the period, including superannuation paid during the quarter.

For personal use only

7.	**Financing facilities** *Note: the term "facility' includes all forms of financing arrangements available to the entity.* *Add notes as necessary for an understanding of the sources of finance available to the entity.*	**Total facility amount at quarter end $A'000**	**Amount drawn at quarter end $A'000**
7.1	Loan facilities	-	-
7.2	Credit standby arrangements	-	-
7.3	Other (please specify)	-	-
7.4	**Total financing facilities**	-	-

7.5	**Unused financing facilities available at quarter end**	-

7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.

N/A

8.	**Estimated cash available for future operating activities**	**$A'000**
8.1	Net cash from / (used in) operating activities (item 1.9)	(3,048)
8.2	Cash and cash equivalents at quarter end (item 4.6)	34,290
8.3	Unused finance facilities available at quarter end (item 7.5)	-
8.4	Total available funding (item 8.2 + item 8.3)	34,290
8.5	**Estimated quarters of funding available (item 8.4 divided by item 8.1)**	11.25

Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.

8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:

8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

Answer:
N/A

8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

Answer:
N/A

8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Answer:
N/A

Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.

For personal use only

Compliance statement

1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.

2 This statement gives a true and fair view of the matters disclosed.

Date: 28 July 2026

Authorised by: The Board of Racura Oncology Limited
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.

2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.

3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.

4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [*name of board committee – eg Audit and Risk Committee*]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".

5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.

For personal use only